| Literature DB >> 33937571 |
Shohei Yamamoto1,2, Akihito Tanaka3, Shinji Kobayashi3, Yusuke Oshiro3, Mitsuru Ozeki3, Kenji Maeda4, Kouki Matsuda4, Kengo Miyo5, Tetsuya Mizoue1, Wataru Sugiura6, Hiroaki Mitsuya7, Haruhito Sugiyama8, Norio Ohmagari9.
Abstract
We assessed the consistency of seropositive results of three rapid immunoassays (Kits A, B, and C) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to highly accurate serological tests (Abbott and Roche) among healthcare workers in a hospital in Tokyo. The seroprevalence of SARS-CoV-2 immunoglobulin G was 0.41%, 2.36%, and 0.08% using Kits A, B, and C, respectively. Of the 51 samples that were seropositive on any rapid test, all were seronegative on both the Abbott and the Roche assays. Given that the seroprevalence of SARS-CoV-2 immunoglobulin G varied widely according to the choice of rapid test and the rapid test results were inconsistent with the results of highly accurate tests, the diagnostic accuracy of rapid serological tests for SARS-CoV-2 should be assessed before introducing these tests for point-of-care testing or surveillance. 2021, National Center for Global Health and Medicine.Entities:
Keywords: COVID-19; SARS-CoV-2; immunoassay; serological tests; seroprevalence
Year: 2021 PMID: 33937571 PMCID: PMC8071682 DOI: 10.35772/ghm.2021.01022
Source DB: PubMed Journal: Glob Health Med ISSN: 2434-9186